Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Benmelstobart vs Toripalimab + Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma
NCT07446335Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib, benmelstobart in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07446335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446335.